A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Vicasinabinas (Primary)
- Indications Diabetic retinopathy
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms CANBERRA
- Sponsors Roche
Most Recent Events
- 21 Jul 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2022 Planned End Date changed from 1 Jun 2023 to 18 Jul 2023.
- 08 Dec 2022 Planned primary completion date changed from 1 Jun 2023 to 18 Jul 2023.